#### Outbreak risks, cases, and costs of vaccination strategies 1 against wild poliomyelitis in polio-free settings: a modelling 2 study 3

4 5

6 7 8 Megan Auzenbergs<sup>1,2</sup>, Kaja Abbas<sup>1,2</sup>, Arie Voorman<sup>3,4</sup>, Corey Peak<sup>4</sup>, Mark Jit, Kathleen M O'Reilly<sup>1,2</sup>

<sup>1</sup> Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK <sup>2</sup> Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK

 $^{\rm 3}$  Institute for Disease Modelling, Seattle, WA, USA

9 10 <sup>4</sup> Bill and Melinda Gates Foundation, Seattle, WA, USA

11

12 13

14 Corresponding author:

15 Megan Auzenbergs

Megan.auzenbergs@lshtm.ac.uk 16

# 17 Abstract

# 18 Background

Polio eradication was threatened in 2022 by importation of wild poliovirus serotype 1 into Malawi
with subsequent international spread, representing the first wild polio cases in Africa since 2014.
Preventing importations and spread of wild poliovirus is critical, and dependent on population
immunity provided through routine immunisation and supplementary immunisation activities (SIAs).
However, the scale of preventative SIAs has reduced in recent years due to financial constraints.

24

# 25 Methods

We developed a mathematical model of polio transmission dynamics to evaluate the probability of an outbreak, expected number of poliomyelitis cases, and the costs associated with vaccination delivery through routine immunisation (RI), outbreak response SIAs (oSIAs) and preventative SIAs (pSIAs). Across varying levels of routine immunisation coverage, we explore three key strategies: RI+oSIAs, RI+oSIAs+annual pSIAs, and RI+oSIAs+biannual pSIAs.

31

# 32 Results

The annual pSIA strategy (RI+oSIAs+annual pSIAs) had higher costs but greater probability of no outbreaks: under our model assumptions, annual pSIAs result in 80% probability of no outbreaks when routine immunisation coverage ≥50%. The biannual pSIA strategy (RI+oSIAs+biannual pSIAs) costs less and averts more outbreaks than RI+oSIAs, but RI coverage ≥65% was required to achieve equivalent risk of no outbreaks. The strategy with no pSIAs (RI+oSIAs) had the lowest costs but required ≥75% RI coverage to achieve equivalent risk of no outbreaks.

39

# 40 Conclusion

41 Prioritisation of pSIAs must balance outbreak risk against implementation costs, ideally favouring the

smallest manageable outbreak risk compatible with elimination. We infer that there are few short-

43 term risks due to population immunity from RI, but without pSIAs, long-term risks accumulate and

44 can result in outbreaks with potential for international spread. We do not consider the costs of

45 further delaying the eradication timeline or societal implications of outbreaks, both of which

46 emphasise the need for pSIAs.

#### 47 Introduction

48 In 2019, the African Region was certified free from endogenous transmission of wild poliovirus 49 (WPV), with the last case reported in Nigeria in July 2014 (1). However, in early 2022, Malawi and 50 Mozambique reported WPV serotype 1 (WPV1) cases, linked to ongoing circulation in Pakistan (2, 3). 51 The geographic distribution and genetic linkage of these WPV1 cases suggest missed transmission of 52 an unknown geographic extent (2). These WPV1 cases highlight the importance of ensuring high and homogeneous levels of population immunity despite decreasing global incidence and elimination 53 54 within the African continent (4). Historically, WPV1 outbreaks in Africa had a varied epidemiology-55 ranging in size from a few cases to explosive outbreaks that resulted in international spread and 56 wide-scale outbreak responses. This variation can be attributed to population exposure to circulating virus and serotype-specific population immunity against poliovirus, among other factors (5). 57

58

59 Since 2016, the recommended routine immunisation schedule is with bivalent oral polio vaccine 60 (bOPV) and at least 1 dose of the inactivated polio vaccine (IPV) to provide population immunity. 61 However, variable routine immunisation coverage leads to differential population immunity in 62 different countries. The joint assessment of immunization coverage by UNICEF and WHO (WUENIC) 63 estimated in 2021 routine vaccine coverage in Malawi and Mozambique was 93% and 61%, 64 respectively. Also, low levels of population immunity persist in other areas, such as Liberia, where a 65 recent study demonstrated poliovirus antibody seroprevalence was only 60% against serotype 1 (6). 66 Further, the number of circulating vaccine derived poliovirus serotype 1 (cVDPV1) outbreaks has 67 increased since 2022, suggesting that population immunity against this serotype has declined in 68 some areas despite a rise in IPV coverage (which is expected to reduce the incidence of paralysis but 69 has limited impact on transmission) (7).

70

71 The Global Polio Eradication Initiative (GPEI) is responsible for the coordination of activities to 72 support polio eradication. The activities include surveillance for acute flaccid paralysis (AFP) caused 73 by polio infection, environmental surveillance (ES) for poliovirus, and providing polio vaccinations 74 through both supplementary immunisation activities (SIAs) and routine immunisation (through the 75 Expanded Programme for Immunisation (EPI)). The SIAs aim to vaccinate hard-to-reach children 76 otherwise missed by RI (8). Despite an annual expenditure of hundreds of millions of USD, decision 77 makers within polio eradication often must make difficult decisions in resource allocation. The global 78 budget has remained relatively stable over the last decade with noted decreases in the last three 79 years. Alongside, the frequency of preventative supplementary immunisation activities (pSIAs), 80 which aim to strengthen population immunity and prevent the frequency and impact of outbreaks 81 has decreased in almost all countries in Africa since 2017 (Figure 1) (9). However, the annual costs 82 for vaccination and programmatic activities such as antiviral development and vaccine stockpiling 83 carried out by GPEI have increased considerably (10, 11).

84

85 Figure 1. Historical pSIAs and RI coverage for 30 African countries (A) Average 86 number of pSIAs per year from 2013-2017 and 2018-2022 and (B) year of last 87 pSIA and WUENIC estimates of DTP3 coverage. Preventative SIAs were defined as 88 either a national or subnational immunisation day (NID, SNID) with bOPV (or 89 tOPV pre-2016) and did not occur within 365 days of a WPV1 or VDPV1 detection, 90 to distinguish historic pSIAs from oSIAs. Any SIAs that occurred within 365 days of 91 a WPV1 or VDPV1 outbreak were not included in the pSIA count. CAR= Central 92 African Republic; DRC = Democratic Republic of the Congo

93

94 Since the World Health Assembly's 1988 resolution to eradicate polio by the year 2000, economic 95 analyses have informed strategies to progress towards this goal. These studies inferred that polio 96 eradication is cost-effective, assuming all vaccination stops following certification of global

97 eradication (12-14). Together, polio vaccination and achieving global polio eradication are estimated 98 to save approximately 40 million DALYs by 2050 (15). However, existing economic analyses do not 99 consider the cost-effectiveness of specific operational decisions for preventative SIAs (pSIAs) and 100 outbreak response SIAs (oSIAs) given a shrinking budget (16) or are outdated and apply to limited 101 geographies (17). The distinction between pSIAs and oSIAs is important because pSIAs and oSIAs 102 have different strategic goals and funding approaches, and programmatic decisions between 103 vaccination strategies are required imminently, not just in the future context of OPV cessation. We 104 aim to compare strategies of differing frequency of pSIAs to that of RI and oSIAs to identify at what 105 levels of RI the risks of outbreaks and polio cases may outweigh the associated costs of 106 implementing pSIAs. This is an evidence gap identified by stakeholders that is important to address if 107 and when we approach the final few years of WPV1 transmission and start to consider OPV 108 cessation.

109

# 110 Methods

The GPEI works with a fixed annual budget for their operations, based on donations from 111 112 stakeholders. This budget is used to support the GPEI's objectives, including the global interruption 113 of poliovirus transmission. Operationally, the planned budget is further divided into planned SIAs 114 and outbreak response, and additional budget lines (not considered further in this study). Outbreak 115 response includes oSIAs, and planned SIAs are either preventive in nature or used in endemic 116 settings (not consider further here); pSIAs lower the risk of outbreaks due to the increase in 117 population immunity. oSIAs include vaccination following a detected case (or at least two separate 118 environmental detections that were collected from two different ES sites with no overlap in 119 catchment area or collected from the same ES site at least two months apart (18)) and aim to raise 120 population immunity in the affected areas to stop transmission. Operationally, pSIAs and oSIAs differ 121 both in the target populations for vaccination as well as the funding and planning for activities – 122 oSIAs must be implemented quickly and require more resource for rapid mobilisation. In this study, 123 we consider only the risks of WPV1 outbreaks in a polio-free setting; the bOPV and IPV used in RI 124 provide immunity against serotype 1. SIAs using bOPV also provide protection against infection as 125 well as protection against paralysis. Outbreaks of vaccine-derived poliovirus serotype 2 require 126 alternative vaccines and assumptions and are therefore beyond the scope of this analysis.

127

We evaluated different pSIA vaccination strategies in addition to RI and oSIAs for a population of 8 million children under five years of age, reflecting an average population size of a LMIC in Sub-Saharan Africa. We estimated costs alongside health benefits and risks for each vaccination strategy over a five-year time-period to align with the current GPEI timeline for polio eradication. Model outputs from each strategy include: probability of an outbreak, estimated cases of paralytic poliomyelitis and VAPP, number of outbreaks and estimated disability adjusted life years (DALYs) associated with these cases (Figure 2).

- 135
- Figure 2. Health benefits, risks, and costs of polio vaccination. Schematic
   showing the relationships between vaccination, population immunity, paralytic
- 138 poliomyelitis cases, adverse events and subsequent costs.
- 139

# 140 Vaccination strategies

We explored three vaccination strategies (Table 1). We assume that vaccination via RI occurs in all strategies and follows a sequential immunisation schedule that includes 3 doses of bOPV given orally via drops in the mouth and 1 dose IPV administered intramuscularly or subcutaneously. The first two comparator strategies (RI+oSIAs+annual pSIAs and RI+oSIAs+biannual pSIAs) maintain the same

assumptions about baseline RI coverage, but additionally include one pSIA either every year or every
 two years, respectively, across time.

147

148 Table 1. Polio vaccination strategies. RI = Routine Immunisation, oSIA = outbreak response 149 supplementary immunisation activity, pSIA = preventative supplementary immunisation activity. An 150 outbreak response was only conducted if a simulation had at least 1 case of paralytic polio.

Vaccination strategy	Specification		
Baseline strategy	RI + oSIAs *No preventative SIAs* RI + oSIAs + annual pSIAs		
Comparator strategy 1			
Comparator strategy 2	RI + oSIAs + <i>biannual</i> pSIAs		

151

152 In all strategies, we define an outbreak as at least one case of paralytic polio (18). An oSIA is 153 conducted in all simulations for each strategy where at least one case was detected within any 90-154 day interval, in line with the median interval from notification to response as per the standard 155 operating procedures (SOP) for polio outbreaks (18, 19). oSIAs continue until all cases are stopped 156 over the five-year time horizon. We do not account for ES detections in this analysis. Children who 157 were not vaccinated via RI, can receive additional doses of bOPV vaccine through either pSIAs or oSIAs. We assume that all SIAs reach 25% of children missed by RI, as prior evidence suggests that 158 159 SIA coverage can be variable across locations and preliminary analysis of higher coverage for zero-160 dose children resulted in unrealistically high population immunity when compared to empirical data 161 (20, 21). Appendix Table 4 includes a sensitivity analysis of different SIA assumptions.

162

# 163 Model structure

164 We developed a stochastic non-linear mathematical model to simulate polio transmission dynamics, 165 whereby infectious individuals develop either asymptomatic or symptomatic infection, both of 166 which are assumed to be infectious. We specify vaccine induced immunity based on OPV and IPV 167 doses (Appendix Figure 1). In the model, children under five years of age are either susceptible, fully 168 vaccinated and protected from poliovirus infection, or have received an incomplete vaccination series (less than 3 bOPV doses + 1 IPV dose). Each subsequent dose of vaccine corresponds to 169 170 additional protection and an opportunity for a child to seroconvert and be considered fully 171 protected from poliovirus infection. Further explanation of model compartments and transitions is in 172 Appendix Table 1.

173

# 174 Time horizon and model assumptions

175 The modelled time horizon is five years, in line with the current GPEI strategic plan (22). The WPV1 case to infection ratio was assumed to be 1:200, which is consistent with estimates for poliovirus 176 177 serotype 1 (23). For polio, the basic reproductive number,  $R_0$  can vary substantially between 178 locations depending on sanitation and hygiene conditions (24). Here we have used an  $R_0$  of 3 for the 179 primary analysis, supported by recent work exploring the parameter space of variable Ro values in a 180 non-endemic setting in Africa for children under five years of age (20, 25), and explore other  $R_0$ 181 assumptions in a sensitivity analysis (Appendix Table 5). The proportion of children receiving three 182 bOPV doses through RI at 6, 10, and 14 weeks is varied between 25%-100%, and for simplicity is 183 assumed to occur upon entering the model. Children who have not seroconverted following 184 vaccination or did not receive three or more doses of bOPV remain susceptible to infection. The 185 proportion of children vaccinated with one dose of IPV is assumed to be equal to the third dose of 186 bOPV RI coverage, which is in line with WUENIC data (26) (Appendix Figure 2). As of 2020, WHO 187 recommends an additional IPV dose as part of RI (27), however, the number of countries that have 188 introduced IPV2 as of 2023 are limited, therefore, we only consider IPV1 in our model.

#### 189

We assume a fully mixed population of children under five years of age with no heterogeneity in the probability of a child being vaccinated in an SIA or in transmission of poliovirus. Simulations are run for 50 years before virus introduction, then one infection was introduced into the population at the start of the simulation and further importations were assumed to occur randomly at a rate of two importations per year. Different importation rates are reported in a sensitivity analysis in Appendix Table 6. The model was repeated for 1,000 stochastic simulations and run for five years. All models were run using the R package SimInf (28).

197

# 198 Probability of an outbreak occurring

For each vaccination strategy, the probability of an outbreak was calculated using the proportion of stochastic simulations that resulted in at least one case of paralytic polio (i.e., a polio AFP case) over the entire modelled time horizon. The probability of an outbreak is comparable to maintaining elimination in an infection-free setting such as most African countries. This definition is not directly comparable towards the WHO criteria for elimination status (29), but is useful for understanding outbreak risk. We do not include the specific criteria for elimination status as modelling of the processes that lead towards achieving eradication are beyond the scope of this analysis.

206

# 207 DALYs

208 DALYs were calculated for each strategy assuming that in LMICs, the average discounted lifetime DALYs associated with one paralytic poliomyelitis case, with no age-weighting is 14 DALYs per 209 210 paralytic case of polio (30), assuming that one in 200 infections leads to irreversible paralysis and 211 among those paralysed, 5-10% die when respiratory muscles become paralysed (31) and long-term 212 mortality is approximately 20% higher in paralytic polio cases than the general population (32). The 213 proportional contribution of YLD (years lost to disability) and YLL (years of life lost due to premature 214 mortality) assuming 14 DALYs on average per case is 60% YLDs on average per case in addition to 215 40% YLLs on average per case (33). We assume no international transmission during outbreaks for 216 calculations of DALYs.

217

# 218 Health and economic outcomes

Incremental costs and incremental outcomes (in terms of DALYs and outbreaks averted) were estimated under each pSIA vaccination strategy in comparison to the baseline comparator (RI+oSIAs). We used a 3% discount rate for costs and 0% for health with no age-weighting, with other discounting assumptions explored in Appendix Figure 5. The total cost for each comparator strategy included baseline RI vaccine costs for both bOPV and IPV. We present both a health system (excludes GPEI costs), and GPEI perspective (includes only GPEI costs) for specification of costs, but do not include indirect costs of vaccination, such as opportunity costs of time spent for vaccination.

226

# 227 Vaccine costs

228 Vaccine costs per dose for bOPV and IPV in Gavi supported countries were obtained from the latest 229 UNICEF update in USD 2023, costing on average \$0.18 and \$2.00, respectively (34, 35) and 230 administrative costs associated with polio RI were obtained from costs used in previous research 231 (36), Appendix Table 3. All costs have been adjusted to 2023 USD. GPEI estimates OPV wastage 232 ranges from 5-15% in SIAs and wastage is lower in SIAs than in RI (37). Estimates of IPV wastage vary 233 between 5-20% in the literature (38) and country-specific analyses from Nigeria and The Gambia 234 suggest IPV wastage can even be higher in practice, exceeding 20% for IPV wastage in some 235 instances (39, 40). Accordingly, the main analysis assumes an average of 10% wastage for OPV in 236 SIAs, 15% for OPV in RI and 15% for IPV, but further wastage assumptions are explored in a 237 sensitivity analysis (Appendix Figure 6).

238

# 239 Data and analysis on SIAs in Africa

240 The Polio Information System (POLIS) (41) was used to obtain SIA data for 2013-2022 and further 241 analysis was done to distinguish preventative campaigns from outbreak response campaigns. We 242 assumed that pSIAs included National or Subnational Immunisation Days (NID, SNID) with bOPV (or 243 trivalent OPV (tOPV) pre-2016) that did not occur within 365 days of a WPV1 or VDPV1 detection by 244 AFP surveillance or ES. Any SIA that occurred within this interval was not included in the overall 245 count of pSIAs. Country level historic pSIA number and year of last pSIA were presented alongside 246 WUENIC estimates of Diphtheria Tetanus Toxoid and Pertussis vaccine third dose (DTP3) coverage 247 (42), an indicator of vaccination via RI as the DTP vaccine is administered concurrently with OPV in 248 the routine immunisation series.

249

# 250 SIA costs

251 The cost per child for both pSIAs and oSIAs was obtained from GPEI data (Appendix Table 7), for 252 which an average across countries within the African Regional Office (AFRO) was used. Historic cost 253 data for oSIAs has been less readily available, therefore, we assume oSIAs cost 2.0 times the cost of 254 a pSIA, as per GPEI estimated costs for 2023. We also explore a range of proportional costs between 255 pSIAs and oSIAs that align with previous assumptions in polio economic modelling (40) (Appendix 256 Figures 7 and 8). Due to the stochasticity of epidemic simulations, there is considerable variability in 257 outcomes for identical assumptions. The number of outbreaks, which affects total estimated costs, is 258 variable and contributes to the variability in expected costs across all strategies (Appendix Figure 3).

259

# 260 Adverse events

261 The expected risk of adverse events, such as vaccine associated paralytic polio (VAPP) in countries 262 using OPV is 1 case of VAPP per 0.9 million doses of bOPV administered and declines with 263 subsequent doses (43). VAPP rate across settings with and without SIAs has been shown to vary (44), 264 although this variation is not well understood or documented. OPV administration following IPV 265 receipt is associated with a further risk reduction of VAPP (43) and is accounted for in model 266 assumptions (Appendix Table 3). VAPP cases contribute to overall risk and costs for each strategy. A 267 VAPP case was considered equivalent to a case of wild-acquired paralytic polio for calculation of the 268 expected costs of VAPP.

269

# 270 Perspectives

Budget and incremental cost results are analysed from both the GPEI and health system perspectives. The GPEI costs include those associated with SIAs and IPV in RI. Treatment costs associated with paralytic polio (including VAPP) are paid for by the country and are included as health system costs. The probability of an outbreak under each vaccination strategy is analysed from both the global perspective for polio eradication and the country health system perspective.

276

# 277 Ethics

278Ethical approval for this project was received from the London School of Hygiene and Tropical279Medicine,projectID15873.

# 280 **Results**

281 On average across all simulations, the expected number of WPV1 cases over five years is greatest in 282 the baseline strategy (RI+oSIAs) and least in the annual pSIA strategy (RI+oSIAs+annual pSIAs) (Figure 283 3A). Under the base case assumptions (including  $R_0$  and proportion of zero dose children reached by 284 SIAs) annual pSIAs achieve and maintain >80% probability of no outbreaks when baseline RI 285 coverage is 50% (Figure 3B). The biannual pSIA strategy (RI+oSIAs+biannual pSIAs) achieves >80% 286 probability of no outbreaks when RI is above 65% and the baseline strategy requires ≥75% RI 287 coverage to achieve >80% probability of no outbreaks. The above results are from simulations 288 assuming two importations per year during the five-year period of simulations. The frequency of 289 importations was varied in a sensitivity analysis (Appendix Table 6); when RI was 50% or lower, the 290 increased frequency of importation had a large increase on the probability of outbreaks, but for 291 simulations with an RI  $\geq$ 75%, the probability of no outbreaks remained above 80%.

- 292
- 293Figure 3. Estimated number of paralytic polio cases and probability that no294outbreaks occur over the five-year modelled time horizon, (A) number of
- 295 expected paralytic polio cases (presenting as a polio AFP case) and (B) probability
- 296 of no outbreaks occurring across all vaccination strategies. Outbreak probability
- 297 was based on 1,000 simulations per vaccination strategy. The red dashed line
- 298 corresponds to 80% probability that no outbreaks occur.

299

Expected VAPP cases over five years are greatest in the annual pSIA strategy, corresponding to the strategy with the greatest number of vaccine doses administered, but fewest expected WPV cases over five-years. Estimated costs from both the health system and the GPEI perspectives are shown in Figure 4. From a health system perspective, estimated costs are lowest in the annual pSIA strategy due to fewer polio cases. From the GPEI perspective, estimated costs of the annual pSIA strategy always exceed the cost of the baseline strategy due to the number of preventative campaigns.

307Figure 4. Health system and GPEI estimated total costs over five years. The size308of the circle is proportional to the mean number of expected paralytic polio cases309across all model simulations. The solid circles correspond to >80% probability the310strategy had no outbreaks over a five-year period.

311

312 Incremental costs per DALY averted by both pSIA strategies in comparison to the baseline strategy 313 are shown in Figure 5 with further explanation of the quadrants in a cost-effectiveness plane 314 (Appendix Figure 9). For non-GPEI costs (Figure 5A), when RI coverage exceeds 50%, points for both 315 pSIA strategies are densely clustered in the bottom-right quadrant highlighting approaches with 316 relatively lower costs and more DALYs averted. Assuming herd immunity is calculated by  $(1 - 1/R_0)$ , 317 when RI coverage exceeds 65%, the point when herd immunity is achieved in this simple 318 homogenously mixed model, the annual pSIA strategy becomes less efficient in averting DALYS. For 319 GPEI costs (Figure 5B), which do not account for treatment or RI bOPV costs, at all levels of RI 320 coverage, the annual pSIA strategy incurs relatively higher costs in comparison to biannual pSIAs, 321 with densely clustered points in top-right quadrant or along the positive y-axis. The cost 322 effectiveness planes are presented in Appendix Figure 5 when a discount rate of 3% has been 323 considered for both health and costs.

324

325Figure 5. Incremental costs per DALY averted. Incremental costs and DALYs326averted under the annual pSIA (RI+oSIAs+annual pSIAs) and biannual pSIA

- 327 (RI+oSIAs+biannual pSIAs) strategies are compared to the baseline strategy
- 328 (RI+oSIAs) assuming a 3% discount rate for costs and 0% discount rate for health.
- 329 The points correspond to 1,000 model simulations. Here, it is assumed that the
- 330 cost per child in an oSIA is two times the cost per child in a pSIA.
- 331

332 Incremental costs per outbreak averted capture the global perspective of polio eradication as a 333 single outbreak under any vaccination strategy has implications for global polio eradication. This 334 analysis has shown a greater number of outbreaks, albeit substantially smaller size, in the annual 335 pSIA strategy in comparison to the baseline strategy when RI coverage is below 45% (under base-336 case assumptions), but the health system incremental costs are kept down by the small number of 337 polio cases (Figure 6A). From the health system perspective, when RI coverage ranges from 45-70%, 338 the annual pSIA strategy averts many outbreaks in comparison to the baseline strategy, but above 339 70% RI coverage, the annual pSIA strategy does not avert many outbreaks and is a costly approach. 340 Both pSIA strategies avert few to no outbreaks when RI coverage exceeds 75%. Under the GPEI 341 perspective, the annual and biannual pSIA strategies avert a similar number of outbreaks above 60% 342 RI coverage, but annual pSIAs have higher incremental costs per outbreak averted, corresponding to 343 the greater number of SIAs conducted (Figure 6B).

344

345 Figure 6. Incremental costs per outbreak averted. Incremental costs and 346 outbreak averted under the annual pSIA (RI+oSIAs+annual pSIAs) and biannual 347 pSIA (RI+oSIAs+biannual pSIAs) strategies in comparison to the baseline strategy 348 (RI+oSIAs) assuming a 3% discount rate for costs and 0% discount rate for health. 349 The points correspond to 1,000 model simulations. Here, it is assumed that the 350 cost per child in an oSIA is two times the cost per child in a pSIA. An outbreak is 351 defined as at least one case of paralytic polio. It is important to note that this 352 figure does not suggest that the RI+oSIAs strategy is better performing at low RI 353 coverage levels. Instead, negative (or no) outbreaks averted by both pSIA 354 strategies at low levels of RI coverage correspond to two phenomena: (i) the 355 RI+oSIA strategy has larger explosive outbreaks when RI coverage is low, so the 356 susceptible population is depleted quicker, whilst the pSIA strategies have much 357 smaller, albeit more frequent, outbreaks when RI coverage is low.

358

359 The implications for decision making are outlined in Table 2. Focussing on estimated risk if historic 360 pSIAs have been regularly conducted, when RI coverage falls below 40%, the annual pSIA strategy 361 averts many cases, so removal of pSIAs entirely would create substantial risk. However, pSIAs do not 362 avert many outbreaks. It is important to note that this finding does not suggest that oSIAs are 363 necessarily better performing at these coverage levels. Instead, the baseline strategy instead leads 364 to quicker depletion of susceptibles or, results in more frequent vaccination via outbreak response 365 following at least one paralytic case, whereas the pSIA strategies only vaccinate the target 366 population annually or biannually. Countries with 50-90% RI coverage and historic pSIAs have a 367 higher probability of no outbreaks occurring, with the outbreak risk reducing with higher RI. 368 However, the risk of an outbreak is not removed entirely until the probability of no outbreaks 369 reaches 100% (when WPV1 transmission is interrupted globally). All strategies require >95% 370 coverage for 100% probability that no outbreaks occur, however, above 80% RI coverage, outbreak 371 probability is low and, if an outbreak does occur, the expected outbreak size is very small. Figure 1 372 further summarises country-level historic pSIAs alongside the date since the last pSIA and current 373 estimates of RI coverage. In summary, countries with <60% RI coverage have conducted more recent 374 and frequent pSIAs and countries with >90% RI coverage have, on average, conducted fewer historic 375 pSIAs per year. However, a few countries that fall below 80% RI coverage have not conducted a pSIA 376 in over a decade.

**Table 2. Policy implications of polio vaccination strategies.** Implications for adopting each vaccination strategy based on a country's RI coverage and historic SIA schedule according to GPEI SIA data (column 2). Average values across all model simulations are references for DALYs averted and outbreaks averted while expected paralytic polio cases are conditional averages amongst simulations that resulted in at least one case. The probability of no outbreaks occurring is obtained from the proportion of model simulations (out of 1,000 simulations) that resulted in zero paralytic cases and

384 correspond to important implications for polio eradication.

	RI	Did country	DALYS	Outbreaks	Estimated risk with annual pSIAs	Estimated risk with biannual pSIAs	Estimated risk relying on oSIAs only†	Implications for
	coverage	conduct pSIAs in the past?	averted*?	averted*?	Average number of polio cases if an outbreak			decision making
			the past?		occurs‡ (Probability no outbreaks occur)			
	35%	L	L	х	5 (35%)	894 (3%)	15,753 (0%)	pSIA removal would have high risks and consequences
	50%	L	L	L	1 (80%)	4 (33%)	3,549 (1%)	Removal of pSIAs altogether could lead to a high risk of outbreaks in subsequent years
	55%	L	L	L	1 (89%)	2 (60%)	617 (3%)	
	60%	L	L	L	1 (92%)	1 (76%)	34 (11%)	
	65%	L	L	L	1 (94%)	1 (85%)	3 (37%)	
	70%	L	х	L	1 (96%)	1 (91%)	1 (72%)	
	80%	L	х	L	1 (97%)	1 (96%)	1 (92%)	Reducing the frequency of pSIAs
	90%	L	х	L	1 (99%)	1 (99%)	1 (98%)	low risk of large outbreaks
	100%	L	х	х	0 (100%)	0 (100%)	0 (100%)	Even if pSIAs are removed, there is low to no risk of outbreaks

385 \* Estimated DALYS and outbreaks averted are obtained from the annual pSIA strategy

386 **†** Estimated risk is obtained from the oSIA strategy assuming no pSIAs occur

387 ‡ Expected paralytic polio cases were calculated by taking the average number of paralytic polio cases across all stochastic model

388 simulations that had <u>at least one</u> case, so this is the average number of polio cases if an outbreak occurs

# 389 **Discussion**

390 The key messages of our study are: (i) with higher RI coverage of three doses of bOPV and 1 dose 391 IPV, the probability of outbreaks reduces considerably – under our model assumptions, outbreak 392 size and risk are minimal when RI is above 65%. At lower values of RI, specific vaccination strategies 393 should be considered; (ii) in scenarios where RI is below 50%, annual pSIAs limit outbreak risk and 394 result in high cost, an annual pSIA strategy when RI is 50-80% results in a low probability of 395 outbreaks and continues to be costly, (iii) biannual pSIAs require higher baseline RI coverage (65%) 396 to achieve an equivalent probability of no outbreaks, but the reduction in cost has few negative 397 outcomes; (iv) a strategy with only RI and oSIAs implicitly accepts some level of outbreak risk, but if 398 RI is above 70-80% the risk of outbreaks is considerably less than other settings where RI is below 399 this value.

400

401 At low levels (<50%) of RI coverage, the probability of outbreaks is high (99%) following an 402 importation if pSIAs do not occur at any frequency. Further, the incremental costs show a clear 403 benefit of a pSIA strategy, outweighing the increased number of expected VAPP cases and cost of 404 vaccination. Countries such as Madagascar or South Sudan where 55% and 49% of the population 405 under five years of age, respectively, are vaccinated with three or more DTP doses (used to 406 approximate polio RI), have many subpopulations that could benefit from regular pSIAs. Indeed, 407 between 2018-2022 South Sudan has implemented annual pSIAs, and Madagascar has implemented 408 oSIAs in response to cVDPV1. Some countries in Africa have many subpopulations that fall towards 409 the middle or upper range of analysed RI coverage estimates. In both Burkina Faso and Sierra Leone, 410 for example, future SIAs would not seem necessary as routine immunisation coverage of three doses 411 of bOPV and 1 dose IPV exceeds 90% without reliance on historic pSIAs, unless there are 412 subpopulations with substantially lower coverage. The proportion of the population in Malawi that 413 has received three doses of bOPV peaked in 2011, but has been unstable since, falling to 83% in 414 2016 (26), with no historic reliance on pSIAs. WPV1 was reported in Malawi and local transmission 415 and international spread has since been reported. In our analysis, RI exceeding 80% would be 416 unlikely to result in an outbreak, but we have not included heterogeneity in immunity in the 417 simulations, likely over-estimating the probability of no outbreaks. It may also be that the frequency 418 of WPV1 importation was under-estimated for the Malawi setting, and close monitoring of migration 419 routes from endemic countries remains an important component of preventing polio outbreaks. 420 Whilst WHO now recommends two doses of IPV (IPV2) as part of RI, many countries in Africa have 421 not yet implemented this strategy. As the number of countries adopting this policy decision 422 increases, future studies will be needed to analyse the impact of IPV2.

423

424 Our study has health policy implications for decision making on global polio eradication. Despite the 425 high costs, the ability of pSIAs to decrease the probability of an outbreak is an important consideration for polio eradication. Should the GPEI adopt an annual pSIA strategy irrespective of 426 427 estimated RI and importations? Annual pSIAs that include all children under five years of age in 428 LMICs in Sub-Saharan Africa would consume most of the GPEI annual budget for activities and would 429 be an inefficient use of funds, potentially reducing funds for other activities (surveillance, 430 vaccination against other serotypes). However, prioritising SIAs in countries with low RI and 431 perceived risk of introductions is a necessary compromise to which GPEI already adheres, and here 432 we provide a framework to support decision making. When considering the vaccination strategies 433 based on perceived outbreak risk (as described here) and the fixed budget for these activities, we 434 must balance making the best use of limited resources while limiting WPV1 outbreak risk. The GPEI 435 is reliant on a combination of country donations and philanthropic contributions to support 436 activities, and budget has remained the same or reduced since 2010 and reduced further since the 437 COVID-19 pandemic (45, 46). From the perspective of donors committing to polio eradication, 438 reducing commitment prior to WPV1 interruption is a false saving: for every outbreak experienced, 439 the timeline to WPV1 interruption become longer and the costs of eradication grows (22). Renewed

commitment by donors was requested in 2022 (47) in light of the 2022-2026 Strategic Plan and
 these commitments remain essential to resource the activities needed to meet the objectives of
 polio eradication, including interrupting WPV transmission.

443

444 Our study has limitations. The main results assume a  $R_0$  of 3 in a homogenous population (both with 445 respect to transmission and population immunity), a frequency of poliovirus introduction of two 446 infections per year and SIAs reaching 25% of children missed by routine vaccination. These 447 assumptions are a necessary simplification of real-world complexity. Several assumptions for  $R_0$ , 448 poliovirus introductions, and SIA reach were considered in a univariate sensitivity analysis. Should 449 SIAs reach up to 50% of zero-dose children, the impact of SIAs on reducing outbreak risk is further 450 reduced, consequently for the same costs a better outcome is achieved. Assuming a higher  $R_0$  and 451 increasing the frequency of importations would also increase the outbreak risk. One of the most 452 uncertain inputs of the analysis is importation rate: as poliovirus infection is typically asymptomatic 453 this is not directly observable (although ES has frequently illustrated introductions in the absence of 454 AFP cases (48)), and due to the changing epidemiology of polio globally, the importation rate will 455 vary in time. We have not considered heterogeneity in the population. If there are pockets of the 456 target population with higher rates of transmission and/or lower vaccination coverage, then the 457 probability of an outbreak occurring would be higher. Additional discussion on the model framework 458 is presented in Appendix Section 1, page 5.

459

460 Further, the model structure assumes that children are vaccinated when they are born into the 461 population, not accounting for infection prior to vaccination. Because the average age of infection 462 with poliomyelitis occurs after the vaccination schedule of bOPV given at 6, 10 and 14 weeks of age 463 alongside the effect of maternal antibodies, this limitation is unlikely to impact the expected number 464 of AFP cases. However, because the size of the birth cohort vaccinated may be overestimated in the 465 absence of infant mortality assumptions, the costs of RI may be over-estimated here. Additionally, 466 we do not include indirect costs of vaccination, such as opportunity costs of time spent for 467 vaccination, which may result in an underestimation of costs across all strategies. The indirect 468 benefits of these additional interventions (such as productivity increases from averting polio cases) 469 are also not quantified in the costs and benefits of SIAs described here, therefore the deaths and 470 burden averted are polio specific and exclude indirect economic effects, in contrast to some other 471 analyses. Since 2020, pSIAs have been reduced or stopped altogether across most LMICs in Sub-472 Saharan Africa, meaning 2023 represents the fourth consecutive year of diminished immunity. This 473 analysis does not directly assess the consequences of this diminished immunity but presents 474 baseline research that can be used to inform these future research questions. We do not consider 475 the costs of further delaying the eradication timeline through outbreaks, or the societal implications 476 of outbreaks on polio eradication, both of which may further emphasise the need to implement 477 pSIAs even when the outbreak risks are small. By limiting our analysis to a five-year time horizon, we 478 underestimate the benefits of SIAs (particularly pSIAs) as they will increase the likelihood of 479 eradication, meaning that control efforts after eradication can be scaled back (though not stopped). 480 Further, the pSIA health system costs only consider the geographical remit stated in the model and 481 ignores the potential for further international spread. International spread would be far more likely 482 with larger outbreaks, consequently the health system costs are under-estimated.

483

In settings that have not recently experienced a WPV1 outbreak, it is challenging to decide between responding to short-term versus long-term risks, especially with a fixed budget. From the global perspective striving to achieve polio eradication, investing in pSIAs results in a greater probability of polio elimination, but still require justification in a pragmatic environment of finite resources. Therefore, future funding provisions and advocacy for the importance of pSIAs rely on research that communicates risk and burden in their absence. Here, we communicate the utility of different vaccination strategies and critically assess the risks associated with adopting different strategies

491 given baseline RI coverage. Decisions made solely based on fixed budget, cost-effectiveness or 492 burden reduction may not fully capture all consequences or benefits associated with adopting a 493 particular vaccination strategy. Urgently, as importations of WPV remain a threat to the AFRO 494 region, this analysis serves as an invaluable tool to estimate risk and plan vaccination activities 495 across a range of settings.

496

# 497 Authors' contributions

498 MA and KMOR conceptualised the study. MA curated the data, conducted the modelling analysis, 499 prepared visualisations of results and wrote the original draft. MA, KMOR and KA independently 500 validated the data and results. All authors contributed to reviewing results and editing of the 501 manuscript and have approved the final version. The authors alone are responsible for the views 502 expressed in this article and they do not necessarily present the decisions, policy or views of their 503 affiliated organisations.

504

# 505 Acknowledgements

This project was funded by the Bill and Melinda Gates Foundation (BMGF), OPP1191821. We would
like to thank Rachel M. Burke (BMGF), Grace Macklin (WHO), John Edmunds (LSHTM), Anna Vassall
(LSHTM), Stephan Widgren (SimInf), and others in the GPEI Subgroup for Analysis and Modelling for
their time and feedback over the course of this project.

510

# 511 Declaration of interests

512 The authors have no conflicts of interest to declare.

513

#### 514 Data sharing

515 Simulation code used in the analysis and sample model outputs can be accessed at: 516 https://github.com/mauzenbergs/polio\_econ.

517

# 518 Acronyms

519 Supplementary Immunisation Activities (SIAs), outbreak response SIAs (oSIAs), planned preventative 520 SIAs (pSIAs), Routine Immunisation (RI), Global Polio Eradication Initiative (GPEI), bOPV (bivalent oral 521 polio vaccine), IPV (inactivated polio vaccine), circulating vaccine derived poliovirus (cVDPV), vaccine 522 associated paralytic polio (VAPP), disability adjusted life years (DALYs), wild poliovirus serotype 1 523 (WPV1), WHO (World Health Organization), The United Nations Children's Fund (UNICEF), WUENIC 524 (WHO and UNICEF estimates of national immunization coverage ), acute flaccid paralysis (AFP), 525 environmental surveillance (ES), African Regional Office (AFRO), Bill and Melinda Gates Foundation 526 (BMGF), low- or middle-income country (LMIC), London School of Hygiene and Tropical Medicine 527 (LSHTM), standard operating procedures (SOP).

528

# 529 **References**

Etsano A, Gunnala R, Shuaib F, Damisa E, Mkanda P, Ticha JM, et al. Progress toward
 poliomyelitis eradication—Nigeria, January 2014–July 2015. Morbidity and Mortality Weekly Report.
 2015;64(32):878.

Malawi Ministry of Health, Global Polio Eradication Initiative, Davlantes E. Notes from the Field:
 Initial Outbreak Response Activity Following Wild Poliovirus Type 1 Detection—Malawi, February 2022.
 Morbidity and Mortality Weekly Report. 2022;71(23):776-7.

5363.Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O'Leary A, et al. Progress Toward Polio Eradication537- Worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650-5.

538 4. McCarthy K, Howard W, Yousif M, Moonsamy S, Suchard M. The show is not over-wild-type 539 polio in Malawi is a wake up call and an opportunity for elimination efforts. International Journal of 540 Infectious Diseases. 2022.

541 5. O'Reilly KM, Lamoureux C, Molodecky NA, Lyons H, Grassly NC, Tallis G. An assessment of the 542 geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. BMC Infect Dis. 543 2017;17(1):367.

544 6. Stephen B Kennedy GRM, Gloria Mason Ross. Poliovirus antibodies following two rounds of 545 campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based 546 seroprevalence survey. Lancet Global Health. 2023.

Franco-Paredes C, Rodriguez-Morales AJ, Henao-Martínez AF, Carrasco P, Tuells J. The growing
 threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era. The Lancet Infectious Diseases.
 2022;22(10):1412-4.

550 8. Global Polio Eradication Initiative. Polio endgame strategy 2019-2023: eradication, integration, 551 certification and containment. World Health Organization; 2019.

552 9. Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, et al. Analysis of 553 population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022.

55410.GlobalPolioEradicationInitiative.GPEIMulti-yearBudget2019-2023:EnablingGPEIto555Interrupt Poliovirus Transmission & Achieve Certification.

55611.Thompson KM, Kalkowska DA. An updated economic analysis of the Global Polio Eradication557Initiative. Risk Analysis. 2021;41(2):393-406.

Thompson KM, Tebbens RJD. Eradication versus control for poliomyelitis: an economic analysis.
 The Lancet. 2007;369(9570):1363-71.

56013.Zimmermann M, Hagedorn B, Lyons H. Projection of Costs of Polio Eradication Compared to561Permanent Control. The Journal of Infectious Diseases. 2019;221(4):561-5.

56214.Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to563support global polio eradication. Expert Rev Vaccines. 2020;19(7):661-86.

564 15. Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective.
565 Vaccine. 2003;21(7):702-5.

Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance
and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J
Vaccines Vaccin. 2016;7(5).

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling Strategies to Increase Population
 Immunity and Prevent Poliovirus Transmission in 2 High-Risk Areas in Northern India. The Journal of
 Infectious Diseases. 2014;210(suppl\_1):S398-S411.

572 18. Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus 573 event or outbreak 2022 [Version 4:[Available from: https://polioeradication.org/wp-574 content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-575 Outbreak-20220417\_OBR\_SOP\_final\_pre\_pub\_website.pdf.

57619.Blake IM, Chenoweth P, Okayasu H, Donnelly CA, Aylward RB, Grassly NC. Faster Detection of577Poliomyelitis Outbreaks to Support Polio Eradication. Emerg Infect Dis. 2016;22(3):449-56.

57820.Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, et al. The role of older children and579adults in wild poliovirus transmission. Proceedings of the National Academy of Sciences.5802014;111(29):10604-9.

581 21. Voorman A, Lyons HM. Measuring polio immunity to plan immunization activities. Vaccine. 582 2016;34(48):5946-52. 583 World Health Organization, Global Polio Eradication Initiative. Polio eradication strategy 2022-22. 584 2026: delivering on a promise. 2021. 585 23. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis 586 deconstructed. American journal of epidemiology. 2010;172(11):1213-29. 587 24. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Polio Vaccine Viruses: 588 Implications for the Global Poliomyelitis Eradication Initiative. American Journal of Epidemiology. 589 1999;150(10):1001-21. 590 25. McCarthy KA, Chabot-Couture G, Shuaib F. A spatial model of Wild Poliovirus Type 1 in Kano 591 State, Nigeria: calibration and assessment of elimination probability. BMC Infectious Diseases. 592 2016;16(1):521. 593 World Health Organization. Poliomyelitis vaccination coverage. 26. 594 27. World Health Organization. Weekly Epidemiological Record, 2020, vol. 95, 22 [full issue]. 595 2020;95(22):241-56. 596 Widgren S, Bauer P, Eriksson R, Engblom S. SimInf: An R package for data-driven stochastic 28. 597 disease spread simulations. arXiv preprint arXiv:160501421.2016. 598 29. Dowdle WR. The principles of disease elimination and eradication. Bulletin of the World Health 599 Organization. 1998;76(Suppl 2):22. 600 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, et al. Economic 30. 601 analysis of the global polio eradication initiative. Vaccine. 2010;29(2):334-43. 602 World Health Organization. Poliomyelitis 31. [Available from: https://www.who.int/news-603 room/fact-sheets/detail/poliomyelitis. 604 32. Nielsen NM, Rostgaard K, Juel K, Askgaard D, Aaby P. Long-term mortality after poliomyelitis. 605 Epidemiology. 2003:355-60. 606 World Health Organization. The global burden of disease: 2004 update: World Health 33. 607 Organization; 2008. 608 34. UNICEF. Inactivated Polio Vaccine (IPV) price data [Available from: 609 https://www.unicef.org/supply/media/16266/file/IPV-vaccine-prices-14032023.pdf. 610 35. UNICEF. oral data 2022 polio vaccine price [Available from: 611 https://www.unicef.org/supply/media/12671/file/oral-polio-vaccine-price-data-08062022.pdf. 612 36. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine 613 policy options: 2019–2029. Risk Analysis. 2021;41(2):364-75. 614 UNICEF. Guidance Note on Cold Chain Logistics and Vaccine Management During Polio 37. 615 Supplementary Immunization Activities. UNICEF, New York, NY; 2015. 616 Mvundura M, Hsu J-S, Frivold C, Kristensen D, Boyle S, Zehrung D, et al. Evaluating the cost per 38. 617 child vaccinated with full versus fractional-dose inactivated poliovirus vaccine. Vaccine: X. 2019;2:100032. 618 39. Wallace AS, Willis F, Nwaze E, Dieng B, Sipilanyambe N, Daniels D, et al. Vaccine wastage in 619 Nigeria: An assessment of wastage rates and related vaccinator knowledge, attitudes and practices. 620 Vaccine. 2017;35(48 Pt B):6751-8. 621 40. Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk 622 Analysis. 2021;41(2):349-63. 623 Global Polio Eradication Initiative. Polio Information System. 2023. 41. 624 42. World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage. 625 Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes 43. 626 and epidemiology of poliomyelitis in the United States. Jama. 2004;292(14):1696-701. 627 44. Tebbens RJD, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. Risks of paralytic 628 disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis. 2006;26(6):1471-505. 0.7% 629 45. OECD. The ODA/GNI target history [Available from: а 630 https://www.oecd.org/dac/financing-sustainable-development/development-finance-631 standards/the07odagnitarget-ahistory.htm. 632 46. Philip Loft PB. The 0.7% aid target. 2022.

633 47. Global Polio Eradication Initiative. GPEI calls for renewed commitments to achieve promise of a 634 polio-free world 2022 [Available from: <u>https://polioeradication.org/news-post/global-polio-eradication-</u>

635 <u>initiative-calls-for-renewed-commitments-to-achieve-promise-of-a-polio-free-world/</u>.

636 48. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al. Environmental

surveillance for polioviruses in the Global Polio Eradication Initiative. The Journal of infectious diseases.
 2014;210(suppl\_1):S294-S303.



В

95%

98%

Botswana Ghana 2004

2015





# Total costs over 5 years

Size of the circles is proportion to the number of expected AFP cases Solid points indicate >80% probability of no outbreak



(USD\$2023)

costs

ncremental

# Health system perspective



B

RI + oSIAs + annual pSIAs RI + oSIAs + biannual pSIAs

# Health system perspective



В

RI + oSIAs + annual pSIAs • RI + oSIAs + biannual pSIAs

**GPEI** perspective